Inhibiting c-Met had substantial effects on IL-6-induced proliferation in four out of nine primary samples, although the frequency of this mechanism in primary myeloma patients is hard to estimate due to the low numbers of samples. This evidence concerns the gene MET and plasma cell myeloma.